Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C45H58N10O13 |
| Molecular Weight | 947.0012 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 11 / 11 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C[C@@H]1NC(=O)[C@@H]2CNC(=O)C[C@H](NC(=O)[C@H](CC(=O)N[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3NC(C)=O)NC1=O)C(=O)N[C@@H](CC4=CNC5=C4C=CC=C5)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N2
InChI
InChIKey=NGCNKEZHGRXHNL-WVWQGFTISA-N
InChI=1S/C45H58N10O13/c1-21(2)13-27-39(62)53-31(17-35(59)55-45-36(48-22(3)57)38(61)37(60)33(20-56)68-45)43(66)52-30-16-34(58)47-19-32(44(67)49-27)54-40(63)28(14-23-9-5-4-6-10-23)50-41(64)29(51-42(30)65)15-24-18-46-26-12-8-7-11-25(24)26/h4-12,18,21,27-33,36-38,45-46,56,60-61H,13-17,19-20H2,1-3H3,(H,47,58)(H,48,57)(H,49,67)(H,50,64)(H,51,65)(H,52,66)(H,53,62)(H,54,63)(H,55,59)/t27-,28-,29-,30-,31-,32-,33+,36+,37+,38+,45+/m0/s1
| Molecular Formula | C45H58N10O13 |
| Molecular Weight | 947.0012 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 11 / 11 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
Menarini was developing oral nepadutant (MEN 11420), a potent and selective tachykinin neurokinin-2 receptor antagonist, for the treatment of infant colic. Nepadutant has been used in trials studying the treatment of colic, infantile colic, and infantile functional gastrointestinal disorders. MEN 11420 is a glycosylated derivative of the potent, selective, conformationally-constrained tachykinin NK2 receptor antagonist MEN 10627. MEN 11420 competitively bound with high affinity to the human NK2 receptor stably transfected in CHO cells, displacing radiolabelled [125I]-neurokinin A and [3H]-SR 48968 with Ki values of 2.5+/-0.7 nM (n = 6) and 2.6+/-0.4 nM (n = 3), respectively.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| MEN15596, a novel nonpeptide tachykinin NK2 receptor antagonist. | 2006-11-07 |
|
| Pharmacology of an original and selective nonpeptide antagonist ligand for the human tachykinin NK2 receptor. | 2005-06-01 |
|
| Nepadutant pharmacokinetics and dose-effect relationships as tachykinin NK2 receptor antagonist are altered by intestinal inflammation in rodent models. | 2001-10 |
|
| MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK2 receptor antagonist. | 1998-01 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00655083
Infantile Colic: 0.1 - 0.5 mg/Kg as one single oral dose divided in three age strata (from 6 to 24 weeks old)
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9484857
Nepadutant (MEN 11420) competitively bound with high affinity to the human NK2 receptor stably transfected in CHO cells, displacing radiolabelled [125I]-neurokinin A and [3H]-SR 48968 with Ki values of 2.5±0.7 nM (n=6) and 2.6±0.4 nM (n=3), respectively. In the rabbit isolated pulmonary artery and rat urinary bladder MEN 11420 potently and competitively antagonized tachykinin NK2 receptor-mediated contractions (pKB=8.6±0.07, n=10, and 9.0±0.04, n=12; Schild plot slope=−1.06 (95% c.l.=−1.3; −0.8) and −1.17 (95% c.l.=−1.3; −1.0), respectively). MEN 11420 produced an insurmountable antagonism at NK2 receptors in the hamster trachea and mouse urinary bladder. However, in both preparations, the effect of MEN 11420 was reverted by washout and an apparent pKB of 10.2±0.14, n= 9, and 9.8±0.15, n=9, was calculated in the hamster trachea and mouse urinary bladder, respectively.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:23:45 GMT 2025
by
admin
on
Mon Mar 31 18:23:45 GMT 2025
|
| Record UNII |
XW59TYL1XH
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29712
Created by
admin on Mon Mar 31 18:23:45 GMT 2025 , Edited by admin on Mon Mar 31 18:23:45 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
XW59TYL1XH
Created by
admin on Mon Mar 31 18:23:45 GMT 2025 , Edited by admin on Mon Mar 31 18:23:45 GMT 2025
|
PRIMARY | |||
|
CHEMBL1908318
Created by
admin on Mon Mar 31 18:23:45 GMT 2025 , Edited by admin on Mon Mar 31 18:23:45 GMT 2025
|
PRIMARY | |||
|
SUB09196MIG
Created by
admin on Mon Mar 31 18:23:45 GMT 2025 , Edited by admin on Mon Mar 31 18:23:45 GMT 2025
|
PRIMARY | |||
|
DB12538
Created by
admin on Mon Mar 31 18:23:45 GMT 2025 , Edited by admin on Mon Mar 31 18:23:45 GMT 2025
|
PRIMARY | |||
|
C84001
Created by
admin on Mon Mar 31 18:23:45 GMT 2025 , Edited by admin on Mon Mar 31 18:23:45 GMT 2025
|
PRIMARY | |||
|
183747-35-5
Created by
admin on Mon Mar 31 18:23:45 GMT 2025 , Edited by admin on Mon Mar 31 18:23:45 GMT 2025
|
PRIMARY | |||
|
DTXSID801032036
Created by
admin on Mon Mar 31 18:23:45 GMT 2025 , Edited by admin on Mon Mar 31 18:23:45 GMT 2025
|
PRIMARY | |||
|
100000084173
Created by
admin on Mon Mar 31 18:23:45 GMT 2025 , Edited by admin on Mon Mar 31 18:23:45 GMT 2025
|
PRIMARY | |||
|
7719
Created by
admin on Mon Mar 31 18:23:45 GMT 2025 , Edited by admin on Mon Mar 31 18:23:45 GMT 2025
|
PRIMARY | |||
|
9876321
Created by
admin on Mon Mar 31 18:23:45 GMT 2025 , Edited by admin on Mon Mar 31 18:23:45 GMT 2025
|
PRIMARY | |||
|
Nepadutant
Created by
admin on Mon Mar 31 18:23:45 GMT 2025 , Edited by admin on Mon Mar 31 18:23:45 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|